OUR MISSION

Driving innovative science to deliver safer and more effective psychiatric treatments to patients – faster

Amani’s lead program, AM-01, is a fixed-dose combination product that includes clozapine and a Phase 3–ready NCE with worldwide rights in-licensed from AstraZeneca. Amani believes AM-01 has the potential to deliver clozapine’s unmatched efficacy for patients with schizophrenia while addressing clozapine’s most significant safety liability—severe neutropenia—and the burdensome blood-monitoring that limit its use.

Clozapine remains the only medication proven to meaningfully improve symptoms in treatment-resistant schizophrenia and to reduce suicide risk in patients with schizophrenia and schizoaffective disorder. Despite its clinical benefits, it is profoundly underutilized due to safety concerns and monitoring requirements.

AMANI LEADERSHIP